^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etoposide oral

    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor, DNA inhibitor
    Related drugs:
    4d
    Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • etoposide oral • Enweida (envafolimab)
    1m
    Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim)
    1m
    Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Indiana University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Sep 2031
    Enrollment open • Trial completion date
    |
    etoposide oral • zanzalintinib (XL092)
    1m
    Adebrelimab combined with etoposide plus platinum followed by adebrelimab and etoposide soft capsules for maintenance treatment of extensive-stage small cell lung cancer: a single-arm phase II trial (ChiCTR2500111156)
    P4, N=40, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P4 trial
    |
    etoposide oral • AiRuiLi (adebrelimab)
    4ms
    Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy (clinicaltrials.gov)
    P2, N=32, Recruiting, Tang-Du Hospital
    New P2 trial
    |
    etoposide oral • AiRuiLi (adebrelimab)
    4ms
    Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Fudan University
    New P2 trial • Platinum resistant
    |
    Avastin (bevacizumab) • etoposide oral • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6ms
    Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Indiana University | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date
    |
    etoposide oral • zanzalintinib (XL092)
    7ms
    FUS Etoposide for DMG (clinicaltrials.gov)
    P1, N=10, Recruiting, Columbia University | Suspended --> Recruiting
    Enrollment open
    |
    etoposide oral
    8ms
    Aumolertinib in combination with Lastet in the first-line treatment of EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (EVOLUTION): protocol for a single-arm, phase II clinical trial. (PubMed, BMJ Open)
    The results of the study will be disseminated through peer-reviewed journals and presentations at academic conferences. NCT06463171.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Ameile (aumolertinib) • etoposide oral
    8ms
    Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Indiana University
    New P1/2 trial
    |
    etoposide oral • zanzalintinib (XL092)
    8ms
    Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study. (PubMed, Int J Gynecol Cancer)
    Niraparib combined with etoposide showed evidence of antitumor activity in platinum resistant/refractory ovarian cancer after ≤2 lines of platinum based chemotherapy, particularly in patients with a BRCA mutation, homologous recombination deficiency, or primary platinum resistance. This once-a-day oral combination was a convenient option.
    P2 data • Journal • BRCA Biomarker • PARP Biomarker • Platinum resistant
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Zejula (niraparib) • etoposide IV • etoposide oral
    9ms
    TUC-TOC: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=66, Recruiting, Institut Curie | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • etoposide oral